Inovio Pharmaceuticals Investors Urged to Act Before Class Action Deadline Approaches

Inovio Pharmaceuticals Investors Alert: Deadline Approaching

In the swiftly moving world of securities, time is often a critical factor determining the course of legal actions. For investors in Inovio Pharmaceuticals, Inc. (NASDAQ: INO), the clock is ticking toward a significant deadline. Faruqi & Faruqi, LLP, a prominent securities law firm, is currently calling attention to the approaching date of April 7, 2026, which marks the last opportunity for investors to act as lead plaintiffs in a federal securities class action against Inovio Pharmaceuticals.

Faruqi & Faruqi has a long-standing reputation in handling securities litigation, emphasizing the necessity for investors who purchased or otherwise acquired Inovio's shares between October 10, 2023, and December 26, 2025, to consider their legal options promptly. Now is the moment for affected investors to take action if they wish to make a claim regarding any losses incurred during this period. Those individuals are encouraged to reach out to the firm's partner, Josh Wilson, who is directly overseeing the case. Interested parties can contact him through the provided numbers, 877-247-4292 or 212-983-9330 (Ext. 1310).

Background on the Allegations

The class action arises amid serious allegations against Inovio Pharmaceuticals regarding their operational integrity and the reliability of their statements to investors. The complaint points out various potential violations of federal securities laws stemming from false or misleading statements by Inovio and its executives. Key points of contention include:

1. Deficiencies in Manufacturing: Inovio’s manufacturing capabilities for its CELLECTRA device have reportedly fallen short of federal standards.
2. Regulatory Hurdles: The company is unlikely to file its Biologics License Application (BLA) for the INO-3107 treatment with the FDA by the projected date of late 2024 due to insufficient preparatory groundwork.
3. Misrepresentation of Approval Eligibility: Statements made regarding the INO-3107 BLA's prospect for FDA accelerated approval or priority review have been deemed overstated and misleading.

These serious allegations could have substantial implications for both the company and its investors, particularly with the confirmed acceptance of Inovio's BLA under standard review by the FDA on December 29, 2025. Inovio did not provide satisfactory evidence to warrant its request for accelerated approval, resulting in a significant drop in its stock value—a stark $0.56 decrease, equating to a 24.45% plunge to close at $1.73 per share on the same date.

Legal Implications and Next Steps

It is crucial for potential class members in this action to understand their rights and the implications of participating or abstaining from this lead plaintiff opportunity. Those who choose to step forward will have a dedicated role overseeing the litigation on behalf of the class, while absentees may still share in any recovery determined by the court, provided they do not take any actions contrary to their interests.

Faruqi & Faruqi LLP advocates for transparency and encourages any individuals with relevant insights into Inovio's operations—whistleblowers, former employees, and shareholders—to reach out to assist in providing a clearer narrative surrounding the allegations.

For more information about participating in the securities class action or to learn about your legal rights regarding your investments in Inovio Pharmaceuticals, please visit Faruqi & Faruqi's dedicated webpage.

Conclusion

With looming deadlines and critical legal proceedings on the horizon, now is an essential moment for investors in Inovio Pharmaceuticals to assess their positions and the potential ramifications of the ongoing class action. Along with engaging legal counsel such as Faruqi & Faruqi, concerned parties would be prudent to prioritize their next steps as significant resolutions may emerge in the coming weeks and months that could affect the securities landscape moving forward.